Neither BPC-157 nor TB-500 has completed a human randomised controlled trial for ulcerative colitis, wound healing, or pain as of 2026. FDA staff concluded the evidence was inadequate for all three indications. An advisory committee nonetheless voted 8-6 in favour of adding both to the 503A compounding list — a non-binding recommendation that has not yet changed legal compounding status.
What Did the July 2026 PCAC Vote Actually Decide — and Does It Make Compounding Legal?
The Pharmacy Compounding Advisory Committee's 8-6 vote on July 23, 2026 recommended that BPC-157 and TB-500 be added to the FDA's 503A Bulks List. This is advisory only. No fixed statutory deadline requires the FDA to act, and neither compound has a legal compounding pathway until the agency completes formal rulemaking — a process that may take months to years.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound from a bulk drug substance only if that substance appears on an FDA-approved list, the preparation is not essentially a copy of a commercially available product, and other statutory conditions are met. The PCAC vote initiates a rulemaking process; it does not itself create a legal compounding pathway.
The 8-6 margin was narrow. FDA staff scientists had recommended against both compounds in their pre-meeting briefing documents, citing a lack of evidence to support effectiveness and unresolved safety signals. The committee's majority disagreed — but the FDA is not bound by its advisory committees' recommendations, and the agency's own staff position remains on record.
For practitioners and patients, the practical implication is clear: as of mid-2026, compounding pharmacies cannot legally prepare BPC-157 or TB-500 from bulk drug substances under 503A. The PCAC vote represents a potential future pathway, not a present one. Any compounded product currently available operates outside this regulatory framework.
What Does the Evidence Show for BPC-157 in Ulcerative Colitis?
BPC-157 has been studied in preclinical colitis models for over two decades, consistently reducing myeloperoxidase activity and accelerating epithelial repair in rodent models. The FDA's July 2026 PCAC briefing reviewed the one available human dataset — a short enema trial — and concluded the data were inadequate to support efficacy or safety conclusions for ulcerative colitis.
The mechanistic rationale for BPC-157 in inflammatory bowel disease is grounded in three pathways. First, the peptide modulates nitric oxide production through eNOS upregulation, counteracting the cytotoxic NO overproduction that drives mucosal injury in active colitis. Second, it suppresses pro-inflammatory cytokines including TNF-α and IL-6, reducing the inflammatory amplification loop that sustains mucosal damage. Third, it activates FAK–paxillin fibroblast signalling, promoting the epithelial migration required for mucosal restitution.
In the World Journal of Gastroenterology, Sikiric and colleagues documented BPC-157's capacity to resolve rat ischemic colitis across multiple experimental conditions — including both early and late intervention timepoints. Myeloperoxidase activity, a validated marker of neutrophil infiltration and mucosal inflammation, was consistently reduced. These findings are reproducible across independent laboratories, which strengthens the preclinical signal.
The human evidence gap is decisive. The FDA's briefing document explicitly stated that the available clinical data for BPC-157 as an enema for ulcerative colitis were "inadequate to support efficacy and safety" — characterising the trial as short and underpowered. No Phase 2 or Phase 3 RCT in UC has been completed or published. The preclinical signal is mechanistically coherent; the clinical translation remains undemonstrated.
What Is the Evidence Base for TB-500 in Wound Healing?
TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4 (Tβ4) spanning residues 17–23. The parent molecule has Phase 2 human data showing topical application accelerated healing in venous stasis and pressure ulcers by approximately one month. TB-500 itself has no completed human RCT, and the 2026 McGuire scoping review confirmed the human trial gap for TB-500 remains structurally unbridged.
Tβ4 promotes wound healing through actin sequestration and cell migration, VEGF upregulation via HIF-1α stabilisation, and anti-inflammatory modulation of the NF-κB pathway. These mechanisms are well-characterised in preclinical models of dermal, corneal, and cardiac wound repair. The Phase 2 trials conducted by RegeneRx Biopharmaceuticals (NCT00832091) used topical Tβ4 gel — not TB-500 — and the results, while directionally positive, were not sufficient to support regulatory approval.
TB-500 is not Tβ4. The 17-amino-acid fragment retains the actin-binding LKKTETQ motif responsible for cell migration activity, but it lacks the full-length peptide's N-terminal domain, which contributes to additional biological functions including anti-apoptotic signalling. Extrapolating Tβ4 wound-healing data to TB-500 requires the assumption that the truncated fragment replicates the parent molecule's full activity profile — an assumption not validated in head-to-head human studies.
The PCAC's July 2026 review acknowledged the Tβ4 wound-healing signal as biologically credible but noted that no human pharmacokinetic or pharmacodynamic data exist for TB-500 specifically. The committee's 8-6 vote in favour of 503A listing reflected a judgement that clinical need was sufficient to warrant further development — not a finding that current evidence supports clinical use.
How Strong Is the Evidence for BPC-157 in Pain Management?
BPC-157's analgesic evidence is entirely preclinical as of 2026. The Yuan review in International Journal of Molecular Sciences identified three mechanistically distinct pathways: eNOS-mediated nitric oxide modulation via the Src–Caveolin-1–eNOS axis, TNF-α and IL-6 suppression driving peripheral nociceptor sensitisation, and dose-dependent attenuation of neurogenic pain in the formalin Phase 1 model — a spinal-level effect separable from local tissue repair.
The formalin model distinction is clinically relevant. Phase 1 of the formalin test reflects direct nociceptor activation — a spinal-cord-mediated acute pain response — while Phase 2 reflects peripheral inflammation-driven sensitisation. BPC-157 attenuates both phases in rodent models, suggesting analgesic activity that is not simply a downstream consequence of anti-inflammatory or tissue-repair effects. This positions it as a candidate for both acute and inflammatory pain contexts.
Dopaminergic pathway modulation represents a third analgesic mechanism documented in preclinical literature. BPC-157 normalises dopamine turnover in the nigrostriatal pathway and attenuates dopamine-depletion-induced hyperalgesia in rodent models. This central mechanism is distinct from peripheral anti-inflammatory activity and raises questions about potential interactions with dopaminergic medications — a safety consideration that has not been evaluated in humans.
No human clinical trial has evaluated BPC-157 for any pain indication. The analgesic mechanisms are mechanistically grounded and reproducible in preclinical models, but the translation to human pain conditions — including the dose, route, and duration required for clinical effect — remains entirely unknown. The absence of human pharmacokinetic data makes rational dose selection for pain indications impossible by current clinical standards.
What Are the Specific Safety Risks of Compounded BPC-157 and TB-500 Injectables?
Compounded injectable peptides carry four risk categories independent of intrinsic pharmacology: immunogenicity from non-GMP synthesis impurities, endotoxin contamination from bacterial production, sterility failures in compounding environments, and dose inaccuracy from absent validated release testing. These manufacturing risks apply to any compounded injectable peptide, regardless of the active compound's preclinical profile or the PCAC's advisory vote.
Non-GMP peptide synthesis introduces truncated fragments and oxidised residues that can act as neoantigens. For injectable preparations, these impurities bypass the gastrointestinal barrier that would otherwise limit systemic exposure. The FDA's Category 2 designation for both BPC-157 and TB-500 — issued in 2023 and maintained through the July 2026 review — explicitly cited immunogenic potential from impure preparations as a patient safety concern distinct from the compounds' intrinsic biological activity.
Endotoxin contamination from bacterial synthesis is a separate risk. Lipopolysaccharide at levels below standard limulus amebocyte lysate (LAL) test detection thresholds can trigger systemic inflammatory responses in susceptible patients. Compounding pharmacies operating under 503A are not required to meet the same sterility and endotoxin-testing standards as licensed drug manufacturers, and no compounding-pharmacy-level protocol reliably excludes sub-threshold LPS contamination from peptide injectables.
For BPC-157 and TB-500 specifically, the intrinsic oncological safety signal adds a compound-specific risk layer. Both peptides upregulate pro-angiogenic pathways — BPC-157 via VEGFR2, TB-500 via HIF-1α/VEGF — that are mechanistically linked to tumour angiogenesis. The PCAC acknowledged this signal while voting in favour of 503A listing; the committee's position was that the risk was manageable with appropriate patient selection, not that it was absent.
What Does the Evidence Profile for Each Indication Look Like in Structured Form?
The table below maps evidence quality for each compound-indication pair reviewed at the July 2026 PCAC meeting. It distinguishes preclinical signal strength, human evidence status, and FDA staff's formal assessment — three dimensions that frequently diverge for these compounds and that practitioners must weigh independently when counselling patients about compounded preparations.
| Compound | Indication | Preclinical Signal | Human RCT Status | FDA Staff Assessment (July 2026) | PCAC Vote |
|---|---|---|---|---|---|
| BPC-157 | Ulcerative colitis | Strong — MPO reduction, mucosal repair, NO modulation in multiple rodent models | No completed RCT; one short enema trial reviewed and deemed inadequate | Inadequate evidence for efficacy and safety | 8-6 in favour of 503A listing (advisory) |
| BPC-157 | Pain management | Moderate-strong — eNOS/NO pathway, TNF-α suppression, formalin Phase 1 attenuation | No completed or registered human pain trial | No human data; preclinical only | 8-6 in favour of 503A listing (advisory) |
| TB-500 (Tβ4 fragment) | Wound healing | Strong for parent Tβ4; TB-500 fragment data are preclinical only | No completed RCT for TB-500; Tβ4 Phase 2 data exist (topical, not TB-500) | Absent human PK/PD data for TB-500 specifically | 8-6 in favour of 503A listing (advisory) |
| TB-500 (Tβ4 fragment) | Musculoskeletal repair | Moderate — actin-binding cell migration, VEGF upregulation in preclinical models | No completed or registered human trial | No human data; preclinical only | 8-6 in favour of 503A listing (advisory) |
Safety Considerations: What Practitioners Must Document Before Discussing These Compounds With Patients
The July 2026 PCAC vote does not change informed-consent obligations for practitioners discussing BPC-157 or TB-500 with patients. Both compounds remain unapproved, lack human pharmacokinetic data, and carry unresolved oncological safety signals. Practitioners must document unapproved status, the pro-angiogenic risk mechanism, manufacturing quality risks of compounded injectables, and the absence of any validated human dose.
For patients with a personal or family history of cancer, or with known subclinical lesions, the pro-angiogenic mechanism of both compounds creates a theoretically elevated risk profile that must be explicitly addressed. The VEGFR2-mediated angiogenic activity of BPC-157 and the HIF-1α/VEGF pathway activation of TB-500 are mechanistically linked to the angiogenic switch that converts dormant tumour clusters into vascularised, actively growing lesions. This is an unresolved mechanistic concern — not a speculative one — and its documentation in the informed-consent record is a minimum standard.
Practitioners should also document the distinction between the PCAC's advisory vote and legal compounding status. Patients who have read media coverage of the 8-6 vote may believe compounding is now legal or that the compounds are approved. Neither is true. The PCAC recommendation initiates a rulemaking process; it does not authorise compounding.
Any product currently available from a compounding pharmacy operates outside the 503A framework. Until the FDA completes formal rulemaking — for which no statutory deadline exists — the legal status of compounded BPC-157 and TB-500 remains unchanged from the pre-vote position.
For the mechanistic oncological evidence that informed the PCAC's safety discussion, see What Does 2026 Research Show About BPC-157 for Musculoskeletal Healing — Regeneration or Risk? on Peptide Therapy Index. For the specific wound-healing evidence gap for TB-500, see Does TB-500's Wound-Healing Evidence in 2026 Justify Compounding — or Does the Human Trial Gap Remain Unbridged?, also on Peptide Therapy Index. Which Peptides Could Exit the FDA's Compounding Restriction List After the July 2026 Advisory Vote? What Does the FDA Panel's July 2026 Compounding Recommendation Mean for BPC-157, TB-500, and KPV When Human Efficacy Data Are Absent? Why Did FDA Scientists Recommend Against Adding TB-500, BPC-157, and MOTS-C to the Compounding Greenlist in July 2026?